We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
- Authors
J. Tol; A. Cats; L. Mol; M. Koopman; M. Bos; J. van der Hoeven; N. Antonini; J. van Krieken; C. Punt
- Abstract
Summary Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a phase III multicentre trial which included chemotherapy and bevacizumab, who developed a GI ulcer (n = 6), perforation (n = 8) or both (n = 4). The risk of developing a symptomatic GI ulcer or perforation was 1.3% and 1.6%, respectively. Central review of the histology specimens showed ulceration and/or granulation tissue with neovascularisation. The majority (89%) of events developed early during treatment. Given these observations, as well as the relationship between VEGF and mucosal injury healing, we suggest that GI ulcers may occur as a side effect of treatment with bevacizumab and may herald perforation.
- Subjects
ULCERS; BEVACIZUMAB; DRUG therapy; COLON cancer
- Publication
Investigational New Drugs, 2008, Vol 26, Issue 4, p393
- ISSN
0167-6997
- Publication type
Article
- DOI
10.1007/s10637-008-9125-4